HK Stock Market Move | XTALPI (02228) Surges Over 5% in Early Trading; Hair Regrowth Pipeline Enters IND-Enabling Stage, Laying Foundation for Clinical Trial Application

XTALPI (02228) surged over 5% in early trading. As of press time, it was up 5.29% at HK$8.255, with a turnover of HK$86.7942 million. On the news front, XtalPi recently announced that its innovative drug pipeline for hair loss treatment has officially entered the IND-enabling (pre-Investigational New Drug application preparation) research stage. Systematic research on key elements including the efficacy, safety, druggability, and CMC of candidate molecules has been initiated, laying the foundation for an IND application. It is reported that in the field of hair loss prevention, XtalPi has already achieved milestone results on the consumer health side. The company's self-developed "Gemini" molecules XTP-118 and XTP-016 have already been commercialized. It is worth noting that recently, multiple self-developed and empowered pipelines of XtalPi have successively reached key milestones including IND approvals and clinical trial initiations. The concentrated delivery of pipeline results indicates that the R&D system driven by AI and Siasun Robot&Automation is transitioning from single-project validation to multi-project reuse, with its capability to scale up the transformation of innovative assets gradually emerging.